Skip to main content
SpringerLink
Log in

Ibrexafungerp: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-d glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls. Ibrexafungerp has been recently approved for the treatment of vulvovaginal candidiasis (VVC), and it is the first novel antifungal drug class to be approved in more than 20 years. Development for the treatment of recurrent VVC and invasive fungal infections is ongoing. This article summarizes the milestones in the development of ibrexafungerp leading to this first approval for the treatment of VVC in adult and postmenarchal paediatric females.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. SCYNEXIS, Inc. SCYNEXIS announces FDA approval of BREXAFEMME® (ibrexafungerp tablets) as the first and only oral non-azole treatment for vaginal yeast infections [media release]. https://www.scynexis.com/. 2 Jun 2021.

  2. SCYNEXIS, Inc. BREXAFEMME® (ibrexafungerp tablets) for oral use: US prescribing information. 2021. https://www.brexafemme.com/. Accessed 24 Jun 2021.

  3. SCYNEXIS, Inc. SCYNEXIS reports first quarter 2021 financial results and provides corporate update [media release]. http://www.scynexis.com. 17 May 2021.

  4. SCYNEXIS, Inc. SCYNEXIS Inc. announces research collaboration with Merck & Co. Inc. for discovery of novel anti-infective agents [media release]. 26 Jun 2002.

  5. SCYNEXIS, Inc. SCYNEXIS gains worldwide rights to novel antifungal compound [media release]. http://www.scynexis.com. 29 May 2013.

  6. SCYNEXIS, Inc., R-Pharm. SCYNEXIS signs deal with R-Pharm to develop and market novel antifungal compound in Russia and other markets [media release]. http://www.scynexis.com. 10 Sep 2013.

  7. SCYNEXIS, Inc. SCYNEXIS and Hansoh Pharma announce licensing agreement and strategic partnership for ibrexafungerp in Greater China [media release]. http://www.scynexis.com. 17 Feb 2021.

  8. SCYNEXIS, Inc. SCYNEXIS confirms that BREXAFEMME® (ibrexafungerp tablets) qualifies for 10 years of regulatory exclusivity for vaginal yeast infections [media release]. https://www.scynexis.com/. 9 Jun 2021.

  9. Jiménez-Ortigosa C, Perez WB, Angulo D, et al. De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring Echinocandin resistance. Antimicrob Agents Chemother. 2017;61(9):e00833-e917.

    Article  Google Scholar 

  10. Gamal A, Chu S, McCormick TS, et al. Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata. Front Cell Infect Microbiol. 2021;11:642358.

    Article  CAS  Google Scholar 

  11. Marcos-Zambrano LJ, Gómez-Perosanz M, Escribano P, et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017;72(7):1969–76.

    Article  CAS  Google Scholar 

  12. Borroto-Esoda K, Angulo DA, Azie N. Ibrexafungerp demonstrates potent and consistent in vitro activity against > 400 global Candida auris isolates, including isolates with elevated MIC’s to echinocandins [abstract no. 733]. Open Forum Infect Dis. 2020;7(Suppl. 1):S417.

    Article  Google Scholar 

  13. Schell WA, Jones AM, Borroto-Esoda K, et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102-e1117.

    Article  CAS  Google Scholar 

  14. Zhu YC, Barat SA, Borroto-Esoda K, et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922.

    Article  CAS  Google Scholar 

  15. Nunnally NS, Etienne KA, Angulo D, et al. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother. 2019;63(11):e01692-e1719.

    Article  CAS  Google Scholar 

  16. Ghannoum M, Long L, Isham N, et al. Activity of a novel 1,3-beta-d-glucan synthase inhibitor, ibrexafungerp (formerly SCY-078), against Candida glabrata. Antimicrob Agents Chemother. 2019;63(12):e01510-e1519.

    Article  CAS  Google Scholar 

  17. Pfaller MA, Messer SA, Motyl MR, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68(4):858–63.

    Article  CAS  Google Scholar 

  18. Larkin EL, Long L, Isham N, et al. A novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother. 2019;63(5):e02611-e2618.

    Article  CAS  Google Scholar 

  19. Sobel JD, Borroto-Esoda K, Azie N, et al. In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida isolates from women with vulvovaginal candidiasis. Antimicrob Agents Chemother. 2021. https://doi.org/10.1128/aac.00562-21.

    Article  PubMed  Google Scholar 

  20. Ghannoum M, Long L, Larkin EL, et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother. 2018;62(6):e00244-e318.

    Article  CAS  Google Scholar 

  21. Jagadeesan V, Driscoll E, Hao B, et al. Ibrexafungerp or caspofungin in combination with azoles against clinical isolates of Aspergillus, including those resistant to azoles [abstract no. AAR08]. In: ASM Microbe Online. 2020.

  22. Lamoth F, Alexander BD. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59(7):4308–11.

    Article  CAS  Google Scholar 

  23. Lee A, Prideaux B, Zimmerman M, et al. Penetration of ibrexafungerp (formerly SCY-078) at the site of infection in an intra-abdominal candidiasis mouse model. Antimicrob Agents Chemother. 2020;64(3):e02268-e2319.

    Article  CAS  Google Scholar 

  24. Wiederhold NP, Najvar LK, Jaramillo R, et al. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. J Antimicrob Chemother. 2018;73(2):448–51.

    Article  CAS  Google Scholar 

  25. Wiederhold NP, Najvar LK, Olivo M, et al. Ibrexafungerp demonstrates in vitro activity against fluconazole-resistant Candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis. Antimicrob Agents Chemother. 2021;65(6):e02694-e2720.

    Article  Google Scholar 

  26. Petraitis V, Petraitiene R, Katragkou A, et al. Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1→3)-β-d-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2020;64(6):e02429-19.

    Article  Google Scholar 

  27. Borroto-Esoda K, Azie N, Ashbaugh A, et al. Prevention of Pneumocystis pneumonia by ibrexafungerp in a murine prophylaxis model [abstract no. 1251]. Open Forum Infect Dis. 2020;7(Suppl. 1):S643.

    Article  Google Scholar 

  28. Ghannoum M, Isham N, Angulo D, et al. Efficacy of ibrexafungerp (SCY-078) against Candida auris in an in vivo guinea pig cutaneous infection model. Antimicrob Agents Chemother. 2020;64(10):e00854-e920.

    Article  CAS  Google Scholar 

  29. Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–72.

    Article  Google Scholar 

  30. Alexander BD, Cornely O, Pappas P, et al. Efficacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI) [abstract no. 1248]. Open Forum Infect Dis. 2020;7(Suppl. 1):S642.

    Article  Google Scholar 

  31. Spec A, Pullman J, Thompson GR, et al. MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056–62.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Arnold Lee

Authors
  1. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 500 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, A. Ibrexafungerp: First Approval. Drugs 81, 1445–1450 (2021). https://doi.org/10.1007/s40265-021-01571-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01571-5

Search

Navigation